Pharmaust Limited (AU:NUZ) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Neurizon Therapeutics Limited has issued 400,000 fully paid ordinary shares following the exercise of unlisted options, priced at $0.10 each. This move, part of their broader strategy to accelerate treatments for ALS and other neurodegenerative diseases, underscores Neurizon’s commitment to advancing its lead drug candidate NUZ-001. The company remains compliant with relevant corporate regulations, ensuring transparency in its financial operations.
For further insights into AU:NUZ stock, check out TipRanks’ Stock Analysis page.
